INTRODUCTION AND OBJECTIVES: Phase 3, double-blind, multicenter Subcutaneous Testosterone Efficacy and Safety in Adult Men Diagnosed with Hypogonadism (STEADY) trial results of a novel, pre-filled auto-injector are presented.
INTRODUCTION AND OBJECTIVES: As today many men undergo multiple prostate biopsies before undergoing treatment for prostate cancer, the impact of biopsy on functional outcomes after radical prostatectomy (RP) has been questioned. We compared functional outcomes between patients who underwent a single biopsy versus repeat biopsies prior to RP for localized prostate cancer.
METHODS: 1015 consecutive patients underwent RP and pelvic lymph node dissection from January 1996 to April 2015. Continence and potency were assessed at 3, 6, 12 and 24 months. For evaluation of potency, patients who reported absence of erection sufficient for penetration prior to RP and those who did not receive some form of nerve-sparing were excluded. The Chi-square test and the Mann-Whitney U test were used to compare categorical and continuous variables between patients who underwent a single biopsy versus repeat biopsies prior to RP. Multivariable logistic regression models tested whether repeat biopsies prior to RP were a predictor of continence or potency at different time points. A two-sided p value < 0.05 was considered significant.
RESULTS: Overall continence rates were 84%, 92%, 96%, and 98% at 3, 6, 12, 24 months, respectively. Repeat biopsies prior to RP were associated with lower continence rates at 3 months compared to single biopsy (p¼0.03) ( Figure) ; however, no differences were observed at 6, 12, and 24 months. In multivariable analyses adjusting for age, body mass index and Charlson Comorbidity Index, repeat biopsies were associated with a borderline significant lower risk of continence at 3 months (odds ratio 0.68 [95% confidence interval 0.46-1.00; p¼0.051], however not at 6, 12, and 24 months. Overall potency rates were 16%, 33%, 51%, and 55% at 3, 6, 12, and 24 months, respectively. No differences in potency rates between single biopsy versus repeat biopsies were seen at all time points (Figure) . In univariate and multivariable analyses, repeat biopsies were not predictive of potency at any time point.
CONCLUSIONS: Repeat biopsies do not impact mid-term to long-term recovery of continence and potency after RP. These data support the current trend towards active surveillance and delayed local treatment in patients with low-to intermediate-risk prostate cancer. METHODS: This prospective study consisted of 60 patients who underwent successfully primary bulboprostatic anastomosis with a perineal approach and developed erectile dysfunction following surgery between Jan 2012 and Jun 2015. The patients were randomized to VED combined with Tadalafil (10mg) once every two days (Group 1, n¼28) or Tadalafil (10mg) once every two days (Group 2, N¼32) for 6 months. The International Index of Erectile Function-5(IIEF-5), nocturnal penile tumescence (NPT) testing and dynamic color-duplex Doppler e1224
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THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Tuesday, May 16, 2017 ultrasonography (D-CDDU) was used as the evaluation tools. Assessments were made at 2 time points: 1 month and 7 months after urethroplasty. RESULTS: The mean patient age was 31.4AE7.0 years (Group 1) and 33.3AE7.2 years (Group 2) repectively (p>0.05). No patients ended the penile rehabilitation program because of treatment-related adverse events in both groups. In Group 1, 57.1% (16/28) patients have erections sufficient to finish the vaginal intercourse compared to 46.9% (14/32) in Group 2 at 7 months after urethroplasty. At 7 months after urethroplasty, the IIEF-5 score is (16.5AE4.0) and (13.6AE4.3) respectively in Group 1 and Group 2 (p<0.05). According to D-CDDU, the cavernosal artery peak systolic velocity (PSV) is (37.1AE7.4) cm/second and (31.6AE9.7) cm/second (p<0.05), the cavernosal artery end diastolic velocity(EDV) is (4.1AE0.9) cm/second and (4.2AE1.2) cm/second (p>0.05), and the penile length change is (3.1AE0.9) cm and (2.4AE0.9) cm(p<0.05) respectively in Group 1 and Group 2 after drug injection. NPT testing shows that the number of erectile events is (2.4AE2.0) and (2.8 AE1.7) (p>0.05), the duration of erectile events is (12.1 AE4.1) min and (11.5AE4.7)min (p>0.05), and the penile Avg Event Rigidity is (26.9AE10.2) cm and (26.4AE11.6) cm (p>0.05)respectively in Group 1 and Group 2.
CONCLUSIONS: This short term study showed that early use of VED is useful and well-tolerated in the penile rehabilitation for the patients after posterior urethral anastomotic urethroplasty because of PFUDD.
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INTRODUCTION AND OBJECTIVES: Clinical trials have
shown that biological women with anorgasmia possess a smaller clitoral glans and clitoral components farther from the vagina lumen than women with normal orgasmic function. The aim of this study is to evaluate neoclitoris size and location with regard to sexual function in patients undergoing male to female (MtF) gender reassignment surgery (GRS). For the evaluation of the normal post-operative changes and presence of complications, in our Centre, patients underwent MtF GRS performed a pelvic non-contrast MRI at 2-4 weeks after surgery.
METHODS: From May to June 2015 we enrolled, during follow up visits, 40 Italian speaking transsexual women underwent MtF GRS and postoperative MRI in our Centre between 2004-2014. Sexual functioning was assessed using the Italian version of the Female Sexual Function Index (FSFI). MR Scans were acquired with a 1.5T superconductive equipment in sagittal and axial planes using a multichannel phased array coil for parallel imaging. TSE T2-weighed images were obtained with 3-4mm thick contiguous sections. The neovagina and the rectum were distended with gel or a vaginal tutor inserted. Individual pelvic MRIs were reviewed by blinded investigators, the three axes of the neoclitoris were measured and the volume calculated using the ellipsoid formula. The distance between the neoclitoris and the neovagina was measured. Data included demographics, sexual history, previous surgery, partnership status, body mass index (BMI), past and current medical history, chronic medical treatments, education, job.
RESULTS: 22 patients completed the study. The mean age was 34 years (SD 7.44). The majority were Caucasians (N¼20, 91%) and in a relationship (N¼13, 51%). At the MRI neoclitoris mean volume was 1.18 cc (SD 0.43), coronal area 6.80 cm2 (SD 2.4) and 5.33 cm2 (SD 1.34) in sagittal view, the mean distance between neoclitoris and neovagina was 3.38 cm (SD 0.5). There is a statistically significant correlation between the parameter that evaluates the distance between the neoclitoris and the neovagina and the FSFI total score (p < 0.0001). Neoclitoris size did not significantly correlate with FSFI total score (p¼0.76).
CONCLUSIONS: This study showed that, even in patients undergoing GRS, neoclitoris localization could be considered a parameter for evaluating sexual function and that a reduction of the distance between neovagina and neoclitoris is associated with greater sexual satisfaction. Neoclitoris size seems not to affect MtF sexual function. 
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